The unique annual herbaceous Cannabis plant variety ‘DRG1’ is provided. The variety can be distinguished by its outstanding features of phenotypic/morphologic features and phytochemical differences from parent and existing strains.

The unique annual herbaceous Cannabis plant variety ‘DRG1’ is provided. The variety can be distinguished by its outstanding features of phenotypic/morphologic features and phytochemical differences from parent and existing strains.

The unique annual herbaceous Cannabis plant variety ‘DRG2’ is provided. ‘DRG2’ is intended for use as a medicinal herb for sale in Cannabis dispensaries, and was developed for PTSD, stress, and anxiety.

The unique annual herbaceous Cannabis plant variety ‘DRG2’ is provided. ‘DRG2’ is intended for use as a medicinal herb for sale in Cannabis dispensaries, and was developed for PTSD, stress, and anxiety.

A new hop plant named ‘HBC 695’ is disclosed. ‘HBC 695’ is used for its exceptional and unique aromatic qualities, and is suitable for beer flavoring.

A new hop plant named ‘HBC 695’ is disclosed. ‘HBC 695’ is used for its exceptional and unique aromatic qualities, and is suitable for beer flavoring.

A spectrum for promoting growth of cannabis plants. The spectrum comprises adding an irradiation of red light with peak wavelength at 655-690 nm into an indoor growing environment of cannabis to improve the levels of THC and CBD, the cannabinoid substances in cannabis. A ratio of photon number of the red light to the photon number of the entire light source is in a range from 40% to 70%. While maintaining the light intensity and other growth conditions, the yields and levels of THC and CBD, the cannabinoid substances in cannabis, can be increased by up to 32.48%.

The present disclosure relates generally to new cannabis plants, including parts, extracts and uses thereof, comprising a cannabinoid profile enriched for total THC (i.e., Δ-9-tetrahydrocannabinol (THC) and Δ-9-tetrahydrocannabinolic acid (THCA), total CBG (i.e., cannabigerol (CBG) and cannabigerolic acid (CBGA)), and total THCV (i.e., tetrahydrocannabivarin (THCV) and tetrahydrocannabivarinic acid (THCVA)).

The present disclosure relates generally to new cannabis plants, including parts, extracts and uses thereof, comprising a cannabinoid profile enriched for total THC (i.e., Δ-9-tetrahydrocannabinol (THC) and Δ-9-tetrahydrocannabinolic acid (THCA), total CBG (i.e., cannabigerol (CBG) and cannabigerolic acid (CBGA)), and total THCV (i.e., tetrahydrocannabivarin (THCV) and tetrahydrocannabivarinic acid (THCVA)).

The unique annual herbaceous Cannabis plant variety ‘DRG2’ is provided. ‘DRG2’ is intended for use as a medicinal herb for sale in Cannabis dispensaries, and was developed for PTSD, stress, and anxiety.